Viatris (VTRS) Q3 2026 earnings review
Viatris raises its profit outlook, but factory halts stall sales
Viatris, the maker of Lipitor, Viagra and generic medicines, grew profit and cash flow even as factory stops in India kept sales unchanged. Third-quarter revenue held at $3.75 billion because 14% growth in Greater China offset declines in Europe, Japan and emerging markets. Interim finance chief Paul Campbell lifted the full-year cash profit outlook by $100 million to $4.5 billion, which by our math leaves fourth-quarter cash profit growing about 6%.
| Total revenue | $3,749.5M 0% from a year ago (-0.3% exact) |
|---|---|
| Gross margin, excluding one-offs | 58.0% +2.1 percentage points from a year ago |
| Profit per share, excluding one-offs | $0.71 +6% from a year ago |
| Full-year cash profit outlook | Raised $100M middle of the range: $4.50B (+8%) |
⚖️ Verdict: 🟢 Bullish
The story got better because cost cuts and higher-margin branded drugs are lifting earnings even when revenue stalls. Viatris also used its cash to buy pain-drug maker Pacira BioSciences for $1.65 billion while winning approvals for Ryzumvi in the US and Wakix in Japan. The bad news: regulators flagged the Nashik plant in India, forcing an October shutdown that doubled the second-half supply hit to $200 million and contributed to trimming the new product sales target.
The question now is whether Viatris can accelerate revenue in 2027 once Pacira closes and the Indian plant restarts. Bulls see Pacira, new launches and $400 million of multi-year cost cuts driving steady growth; bears see China's hospital price rules and recurring Indian factory halts eating those gains. Management's 2027 outlook and the Nashik restart in the first quarter will settle it.
🐂 Bull Case
Cost Cuts and Brand Mix Lifted Gross Margin
Viatris is trying to grow profit faster than sales by trimming expenses and selling more branded medicines. Interim finance chief Paul Campbell pointed to "operational momentum across our higher-margin businesses and continued focus on cost discipline" as the driver of the quarter.
The numbers back him up even though total revenue stood still at $3.75 billion. Gross margin excluding one-offs rose 2.1 percentage points from a year ago to 58.0%, because the cost of making its products fell 2.1 points of revenue to 42.0%. Research and development and overhead stayed flat as a share of sales, so operating profit excluding one-offs rose 7% to $1.12 billion.
That margin expansion allowed Viatris to raise its full-year cash profit and earnings per share targets despite factory stops in India. What to watch: fourth-quarter gross margin excluding one-offs when full-year results arrive in February. Holding above 56.5% would show that cost savings are offsetting generic price pressure.
Pacira Deal and Approvals Refresh the Pipeline
Because older off-patent drugs slowly lose sales to generic rivals, Viatris needs new medicines to grow through the end of the decade. In October the drugmaker agreed to buy Pacira BioSciences, a maker of non-opioid pain treatments, for $1.65 billion in cash.
- Pacira acquisition: $36.50 per share in cash, or $1.65 billion, expected to close by the end of November 2026
- Gwyn Lo: launched in the US in October as a weekly low-dose contraceptive patch
- Ryzumvi: won US approval in October for presbyopia, expanding its eye-care label
- Wakix: won approval in Japan in September for sleep apnea daytime sleepiness and narcolepsy
Buying an established pain portfolio adds immediate revenue without waiting on risky clinical trials. Campbell said the deal will "have minimal impact on our gross leverage ratio upon expected closing by the end of November", as debt sits at 2.9 times cash profit. What to watch: Pacira's initial revenue contribution when Viatris issues its 2027 outlook in February. A contribution above 2% of total sales would lift the company into its long-term growth target.
Positives this quarter didn't test
Two standing drivers from earlier in the year got no new figures in the third-quarter release.
- Estradiol patch capacity: Viatris previously fulfilled about 70% of orders after a label change lifted demand; the conference call or quarterly filing will show whether factory expansions raised fulfilment.
- Realized restructuring savings: the three-year review targets $400 million in net savings, with about $120 million expected this year; full-year remarks in February will test how much landed in 2026.
🐻 Bear Case
FDA Action at Nashik Doubled the Supply Hit
"Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business," chief executive Scott A. Smith said. Yet quality problems at Viatris's factories in India worsened during the quarter and erased growth outside China.
In September US regulators notified Viatris that the "inspection classification of Company's oral solid dose manufacturing facility in Nashik, India was Official Action Indicated" after a May inspection. Then in October, "out of an abundance of caution, the Company voluntarily suspended manufacturing at the facility to focus on remediation activities" until the first quarter of 2027. Sales in Emerging Markets fell 7% and generic drug sales dropped 3% on "continued supply constraints in Europe and Emerging Markets".
Three months ago Viatris estimated that Nashik disruptions would cut second-half sales by $100 million to $150 million in total. Now it estimates a $100 million hit in the third quarter and another $100 million in the fourth, doubling the bottom of the prior range. What to watch: whether production at Nashik resumes in the first quarter of 2027 as planned. A formal warning letter or import ban would extend the $100 million quarterly drag into next year.
New Product Target Trimmed as Launch Pace Lags
Viatris tracks new product revenues — sales from medicines launched in 2026 or within the prior 12 months — to show its pipeline can replace shrinking older drugs. Until August, the company aimed for $450 million to $550 million from these launches this year.
In the third quarter, new products brought in $115 million, bringing the nine-month total to $287 million. Viatris quietly dropped the upper end of its goal and now expects "approximately $450 million" for the full year. This repeats last year's pattern, when the drugmaker set a $450 million to $550 million target and finished at $324 million.
By our math, hitting even the lowered $450 million mark requires $163 million in the fourth quarter, which is 42% above the third-quarter pace. What to watch: fourth-quarter new product revenue and the Food and Drug Administration decision on fast-acting meloxicam, a pain drug due by December 27. Falling short of $163 million in the fourth quarter would mean Viatris missed its initial launch target two years in a row.
China Growth Slowed Before Hospital Rules Bite
Greater China has been Viatris's main growth engine this year, carrying high profit margins on off-patent brands like Lipitor and Norvasc. Bulls view Chinese retail and e-commerce demand as a lasting driver, while bears worry that new provincial hospital buying rules will cut prices and volumes.
In the third quarter, Greater China net sales grew 14% as reported and 10% at constant exchange rates to $702.6 million. That kept the company's total revenue from falling, as Developed Markets shrank 2%, JANZ (Japan, Australia and New Zealand) fell 6%, and Emerging Markets dropped 7%. However, China's constant-currency growth slowed from 18% in the first quarter and 16% in the second.
The press release gave no figures on how the new Chinese hospital procurement rules affected volumes. What to watch: management's quantification of the China hospital policy on the conference call and fourth-quarter China constant-currency growth. A further drop toward low-single-digit growth would remove the sole offset to declines in Europe and Japan.
Risks this quarter didn't answer
Five standing risks from prior quarters received no new updates in the earnings release.
- Phase 3 trial readouts for selatogrel (heart attack) and cenerimod (lupus): both remain slated for the first half of 2027, when top-line data will decide Viatris's post-2028 growth rate.
- Generic price-fixing and opioid lawsuits: the release showed an $11 million net litigation credit, leaving trial schedules and Pfizer's opioid-sharing dispute for the quarterly filing.
- JANZ price cuts and Amitiza patent loss: JANZ sales fell 6% and Amitiza fell 11% to $36.4 million ahead of potential Japanese generic entry in December 2026.
- US tariff exposure: about half of US generic sales come from abroad; any new trade duties would test gross margin.
- Permanent finance chief search: Paul Campbell remains interim finance chief six months after his predecessor left.
👓 Other Themes
Tax Charges Pushed Accounting Results Into Loss
Under standard accounting rules, Viatris reported a third-quarter net loss of $325.3 million, or $0.28 per share, wider than the $128.2 million loss a year ago. Operating profit actually rose 46% to $261.5 million on lower legal and research costs, but income tax expense jumped from $120.3 million to $453.2 million. Viatris attributed the charge to "an increase in income tax provision due to losses in jurisdictions for which minimal benefit can be realized".
💲 Other KPIs
Cash left after capital spending rose 23.6% from a year ago, lifting the nine-month total to $1.49 billion. Excluding $81 million of deal and restructuring payments, third-quarter free cash flow reached $895 million. Stronger cash generation pushed cash on hand up to $1.79 billion and reduced net debt by 12% since December.
The share count used for profit per share excluding one-offs fell 1.0% from a year ago and 1.0% from last quarter. Viatris has returned $717 million to shareholders in the first nine months of 2026, including about $300 million in share buybacks, and has $700 million left on its buyback authorization.
Stockpiles of raw materials and finished drugs fell 4.3% from $3,999.2 million at the end of December and 2.6% from June. The drop reflects $98.6 million of inventory and equipment write-offs from the February fire at the Nashik plant in India alongside ongoing supply constraints.
🔮 Guidance
Raised. Viatris lifted the bottom of the range by $150 million and trimmed the top by $50 million, moving the middle up $50 million to $14.8 billion (3.5% growth). By our math, that leaves $3.78 billion, or 2.0% growth, for the fourth quarter despite a $100 million Nashik supply hit. Across four quarters, the middle of the range moved $0M, +$50M and +$50M; the outlook excludes Pacira.
Raised. The drugmaker boosted the middle of its cash profit plan by $100 million to $4.5 billion, or 8.2% growth from last year. By our math, that implies $1.07 billion in the fourth quarter, up 6.3% from a year ago. It is the second straight $100 million increase after holding steady in the first quarter (+$0M, +$100M, +$100M).
Raised. Profit per share excluding one-offs moved up $0.08 at the middle of the range to $2.60, representing 10.6% growth for the year. By our math, the full-year plan leaves $0.61 per share for the fourth quarter, up 7.0% from $0.57 a year ago. Across four updates, the midpoint has moved +$0.00, +$0.12 and +$0.08.
Raised. Viatris lifted the bottom of its operating cash flow plan by $125 million, raising the middle by $62.5 million to $2.06 billion (down 10.9% from 2025). By our math, after generating $1.67 billion in the first nine months, the outlook leaves $393 million for the fourth quarter, down from $815.8 million a year ago as restructuring payments continue.
Raised. Standard free cash flow — operating cash flow minus capital spending of $325 million to $400 million — rose $100 million at the middle of the range to $1.7 billion (down 12.2% from last year). By our math, that implies $209 million of free cash flow in the fourth quarter, as the capital spending plan implies $184 million of fourth-quarter factory investments.
Raised. Adding back about $600 million of deal and restructuring payments, the middle of the range rose $100 million to $2.3 billion, or 4.5% growth over 2025. By our math, with $1.80 billion already collected in the first nine months, the plan leaves $500 million for the fourth quarter. The midpoint has risen across four updates by +$0M, +$50M and +$100M.
Cut. Viatris dropped the top end of its $450 million to $550 million launch range and now expects about $450 million for the year. By our math, after recording $287 million in the first nine months, the drugmaker still needs $163 million in the fourth quarter — above the $115 million it delivered in the third quarter.
❓ Key Questions
How much will China's hospital rules cut sales?
Chief executive Scott A. Smith previously said Viatris would be ready in November to explain how China's 31-province hospital buying rules affect the business. With Greater China constant-currency growth slowing from 16% to 10%, investors need the exact price and volume hit.
Which drugs will drive the fourth-quarter launch jump?
Reaching the reduced $450 million new product target requires $163 million in the fourth quarter, up from $115 million in the third. Management did not say how much comes from initial stocking of the Gwyn Lo patch versus older complex generics.
What is required to restart the Nashik factory?
The Food and Drug Administration classified the Nashik plant as Official Action Indicated, and Viatris halted production in October. Investors need to know whether Viatris can resume shipments in the first quarter of 2027 without an agency reinspection.
How much profit will Pacira add in 2027?
Viatris is paying $1.65 billion in cash for Pacira BioSciences late this month and says debt ratios will barely move. Management has not yet shared Pacira's expected 2027 revenue, cost savings, or borrowing cost.